Prescription Drug Procurement and the Federal Budget
This brief commissioned by the Foundation considers areas where Medicare faces limited opportunity for market-based competition and price negotiation to drive down drug spending.
View the Latest: Medicare Part D
Filter
-
-
Medicare Part D 2009 Data Spotlight: The Coverage Gap
ReportThis Medicare Part D data spotlight examines the coverage gap, or "doughnut hole," in Medicare drug plans available in 2009. While in the gap in coverage, Part D enrollees (other than those receiving low-income subsidies) are required to pay 100 percent of total drug costs until they reach the catastrophic coverage level.
-
Medicare Prescription Drug Improvement and Modernization Act Implementation Timeline: June 2004 – December 2006 Key Dates
ReportKey Implementation Dates for the Medicare Prescription Drug Benefit This timeline presents important dates and deadlines of key implementation activities related to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). It runs from the beginning of 2005 through the end of 2006, the first year of the new Medicare drug benefit.
-
Choosing a Medicare Part D Plan: Are Medicare Beneficiaries Choosing Low-Cost Plans?
ReportSince 2006, Medicare beneficiaries have had the opportunity to choose from among dozens of plans to get the Part D prescription drug benefit, facing wide variation in benefits, premiums and cost-sharing.
-
The Exceptions and Appeals Process: Issues and Concerns in Obtaining Coverage Under the Medicare Part D Prescription Drug Benefit
Issue BriefThis issue brief describes how Medicare beneficiaries navigate the Medicare Part D exceptions, appeals, and grievances processes to get access to medically necessary prescriptions not covered under their Medicare prescription drug plans. It identifies and describes policy issues that may make it difficult for beneficiaries to utilize the processes. Issue Brief (.
-
The Medicare Drug Benefit: Beneficiary Perspectives Just Before Implementation – Toplines
Poll FindingThese toplines provide the complete results from a comprehensive survey of seniors on their understanding of and views toward the Medicare drug benefit. The survey of 802 seniors was conducted in late October 2005, prior to the start of the benefit's open enrollment period, which runs from Nov. 15, 2005 to May 15, 2006.
-
Prospects for Retiree Health Benefits as Medicare Drug Coverage Begins – Report
ReportProspects for Retiree Health Benefits as Medicare Drug Coverage Begins:Findings from the Kaiser/Hewitt 2005 Survey on Retiree Health Benefits - Report This report assesses how large businesses that provide retiree health benefits to their workers are responding to the new Medicare drug benefit in 2006, their plans for the future, and the way these responses…
-
An Implementation Perspective on Part D, the Medicare Prescription Drug Program
ReportThis focus group of 12 state Medicaid officials conducted in November 2005 explores the current status and likely results of the Part D dual eligible transition efforts as well as other Part D-related issues of particular importance to states.
-
Observations on the Initial Implementation of the Medicare Prescription Drug Program: Perspectives of State Medicaid Directors Through a Focus Group Discussion
ReportObservations on the Initial Implementation of the Medicare Prescription Drug Program: Perspectives of State Medicaid Directors Through a Focus Group Discussion Medicaid directors express the need to continue to focus on the interaction between Medicaid and the Medicare prescription drug benefit and to address the key system and coordination issues that remain, particularly with the…
-
The Role of Part D for People With HIV/AIDS: Coverage and Cost of Antiretrovirals Under Medicare Drug Plans
Issue BriefThe Kaiser Family Foundation released a new report on the implications of the new Medicare Part D prescription drug benefit for people living with HIV/AIDS. The report looks at the coverage and cost of antiretroviral drugs under the new private, stand-alone Medicare drug plans. Report (.